Intel Corporation
11
3
4
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
Role: collaborator
Intelligent Spine Interface, Clinical (ISI-C)
Role: collaborator
Remote Monitoring of Chronic Illness Patients With a IHAP Home Wireless Hub and Vitals Measurements
Role: collaborator
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy
Role: collaborator
Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions
Role: collaborator
Deployment of American Heart Association Heart Failure Protocols and Content Within the Intel® Health Guide System
Role: collaborator
Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease
Role: collaborator
GADGET-PD Genetic and Digital Diagnosis of Essential Tremor and Parkinson's Disease Trial
Role: collaborator
Assess Measurements of Wireless Cardiac Output Device
Role: collaborator
The Effect of the Use of Computer Game- "My Diabetic Friend" in Children With Type 1 Diabetes
Role: collaborator
Aetna_Intel Medicare Home Biomonitoring Study
Role: collaborator
All 11 trials loaded